Twice-Daily vs. Once-Daily Dolutegravir in Patients With Human Immunodeficiency Virus-Tuberculosis Coinfection Receiving Rifampicin-Based Tuberculosis Therapy

Clin Infect Dis. 2020 Jun 24;71(1):242-243. doi: 10.1093/cid/ciz917.
No abstract available

Keywords: HIV and tuberculosis coinfection; dolutegravir dosage; pharmacokinetics; tuberculosis treatment outcome; virological outcome.

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Comment

MeSH terms

  • Coinfection* / drug therapy
  • HIV
  • HIV Infections* / complications
  • HIV Infections* / drug therapy
  • Heterocyclic Compounds, 3-Ring / adverse effects
  • Humans
  • Oxazines
  • Pharmacology, Clinical*
  • Piperazines
  • Pyridones
  • Rifampin / therapeutic use
  • Tuberculosis* / complications
  • Tuberculosis* / drug therapy

Substances

  • Heterocyclic Compounds, 3-Ring
  • Oxazines
  • Piperazines
  • Pyridones
  • dolutegravir
  • Rifampin